Last Updated

29 May 2020

Imaging and Improvement of Immune Protection against Malaria Parasites (IM3alaria)

Objectives

This international collaborative project proposes to improve protection induced by pre-erythrocytic (PE) vaccines using an innovative double biological-vaccination approach that combines our complementary expertise on targeting antigens to dendritic cells, on lentiviral vectorology and on studying the biology of PE malaria parasites using in vivo imaging. 

This objective will be achieved through:

  1. To elucidate the mechanisms of this antibody-mediated sterilizing protection using in vivo imaging and a library of anti-CSP monoclonal antibodies to determine when, where, how and what kind of antibody is eliminating the parasite in the skin and liver of protected hosts.
  2. To ameliorate this humoral protective protocol by the addition of a strong CD8+ T cell response elicited by the targeting of the CD8 epitope of CSP to dendritic cells using anti-DEC205/DCIR2 hybrid antibodies and lentiviral vectors.
  3. The third level of protection will be added by the incorporation of novel protective PE antigens coming from a functional screening using lentiviral vectors, where the hundred most abundant genes of PE stages are being screened based on their protective activity.

In summary, with this approach, it is intended to characterize sterilizing effector activities at a clonal level using innovative in vivo imaging methods, optimize CD8+ T cell response via new means of targeting antigens to dendritic cells, and test multi-antigenic formulations to broaden the protective responses against the parasite. Thus it is proposed a functional dissection of effectors of protection, a first step toward devising better vaccines on a rational basis, and a stepwise strategy to improve humoral and cellular immune protection centred on the CSP, using the protein alone or in combination with novel protective PE antigens.

Principal Investigator
Rationale and Abstract

The absence of an effective malaria vaccine is a major hurdle towards the control and elimination of this devastating disease. However, the development of a malaria vaccine is encouraged by the possibility of protecting humans, known since the 70’s, through vaccination using multiple and high doses of live attenuated sporozoites, the motile and infectious parasite-stage delivered by mosquitoes. Unfortunately, this method is inappropriate for use in large-scale vaccination protocols due to major operational and economical impediments related to the production, storage and delivery of large numbers of live attenuated parasites in tropical countries. Conversely pre-erythrocytic (PE) sub-unit vaccines, which target sporozoites and liver stages, are more suitable to be used in mass vaccination but only moderately protect humans against malaria as observed for RTS,S, the most prominent PE vaccine candidate based on the circumsporozoite protein (CSP), the major surface protein of sporozoites. In addition, the number of protective PE antigens, among the thousands of possible PE proteins, is extremely limited and these antigens are only poorly protective. 

Study Design

The strategy of this project is based on the use of a relevant pre-clinical rodent malaria model, where mice are extremely susceptible to sporozoite infection. In this model, circumsporozoite protein (CSP) based immunizations are not capable of inducing complete protection against a stringent challenge of sporozoites, like observed in humans. Using this model, a preliminary protocol was developed where anti-CSP antibodies completely protected animals challenged with a stringent dose of 5000 sporozoites. 

Date

2015 Mar - 2019 Mar

Funding Details

$470,027
Grant number: ANR-14-CE16-0030
Project Site